Roche submits breast cancer drug for FDA approval

Roche said it filed trastuzumab-DM1 (T-DM1) for approval with the U.S. Food and Drug Administration (FDA) for people with advanced HER2-positive breast cancer who had previously received other treatments.
A mid-stage phase II study showed that the drug shrank tumors in one-third of women who had received on average seven prior medicines for advanced HER2-positive breast cancer, ............& more.